{"generic":"Mecasermin","drugs":["Increlex","Mecasermin"],"mono":{"0":{"id":"928470-s-0","title":"Generic Names","mono":"Mecasermin"},"1":{"id":"928470-s-1","title":"Dosing and Indications","sub":{"1":{"id":"928470-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy has not been established in children less than 2 years of age<\/li><li><b>Primary IGF-1 deficiency (Severe):<\/b> initial, 0.04 to 0.08 mg\/kg (40 to 80 mcg\/kg) SubQ twice daily<\/li><li><b>Primary IGF-1 deficiency (Severe):<\/b> maintenance, may increase by 0.04 mg\/kg per dose; MAX 0.12 mg\/kg SubQ twice daily<\/li><\/ul>"},"3":{"id":"928470-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Primary IGF-1 deficiency (Severe)<br\/>"}}},"3":{"id":"928470-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928470-s-3-9","title":"Contraindications","mono":"<ul><li>allergy or severe hypersensitivity to mecasermin (rhIGF-1) or any component of the formulation<\/li><li>growth promotion in patients with closed epiphyses<\/li><li>intravenous administration<\/li><li>neoplasia, active or suspected; discontinue therapy if evidence of malignancy subsequently develops<\/li><\/ul>"},{"id":"928470-s-3-10","title":"Precautions","mono":"<ul><li>high-risk activities (eg, driving or operating machinery); limit activities within 2 to 3 hours after dosing, particularly when therapy is initiated, due to hypoglycemic effect<\/li><li>hypersensitivity and allergic reactions, including anaphylaxis, have been reported<\/li><li>hypoglycemic effect, especially in small children; administer shortly before or after a meal or snack; monitoring recommended; may require dose adjustment<\/li><li>intracranial hypertension has occurred; perform funduscopic examinations at initiation and intermittently during therapy<\/li><li>lymphoid tissue (eg, tonsillar and adenoidal) hypertrophy has occurred; monitoring recommended<\/li><li>neonates; gasping syndrome and neurologic toxicity due to benzyl alcohol preservative can occur<\/li><li>scoliosis, history; progression may occur with rapid growth due to mecasermin therapy; monitoring recommended<\/li><li>slipped capital femoral epiphysis may occur with rapid growth due to mecasermin therapy; evaluate limp or complaints of hip or knee pain<\/li><li>report suspected adverse reactions to Tercica at 1-866-837-2422 or to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928470-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928470-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928470-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction, Lipohypertrophy (5% or greater)<\/li><li><b>Gastrointestinal:<\/b>Hypertrophy of tonsils (15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia (42%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Aseptic necrosis of bone<\/li><li><b>Neurologic:<\/b>Raised intracranial pressure, Seizure (5% or greater)<\/li><li><b>Respiratory:<\/b>Dyspnea<\/li><\/ul>"},"6":{"id":"928470-s-6","title":"Drug Name Info","sub":{"0":{"id":"928470-s-6-17","title":"US Trade Names","mono":"Increlex<br\/>"},"2":{"id":"928470-s-6-19","title":"Class","mono":"Endocrine-Metabolic Agent<br\/>"},"3":{"id":"928470-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928470-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"8":{"id":"928470-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928470-s-8-24","title":"Distribution","mono":"Vd: 0.257 L\/kg <br\/>"},"2":{"id":"928470-s-8-25","title":"Metabolism","mono":"liver and kidney <br\/>"},"3":{"id":"928470-s-8-26","title":"Excretion","mono":"0.04 L\/hr\/kg <br\/>"},"4":{"id":"928470-s-8-27","title":"Elimination Half Life","mono":"5.8 hours <br\/>"}}},"9":{"id":"928470-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>use syringes that are small enough to accurately withdraw dose from vial<\/li><li>administer by subcutaneous injection shortly before or after (+\/- 20 minutes) a meal or snack<\/li><li>injection site should be rotated to a different site (upper arm, thigh buttock, or abdomen) with each injection to avoid lipohypertrophy<\/li><\/ul>"},"11":{"id":"928470-s-11","title":"How Supplied","mono":"<b>Increlex<\/b><br\/>Subcutaneous Solution: 10 MG\/ML<br\/>"},"13":{"id":"928470-s-13","title":"Clinical Teaching","mono":"<ul><li>Avoid activities that require alertness (driving, machine operation) within 2 to 3 hours of dosing, particularly during therapy initiation, until a well-tolerated dose is established.<\/li><li>This drug may cause hypertrophy of tonsils, slipped upper femoral epiphysis, or injection site reactions.<\/li><li>Instruct patient to monitor for and report signs\/symptoms of hypoglycemia, especially in small children.<\/li><li>Advise patient to report signs and symptoms of hypersensitivity reaction.<\/li><li>Patient should administer within 20 minutes of a meal or snack. Never give in the absence of food.<\/li><li>Teach patient proper technique and placement of injections. This drug is to be administered subcutaneously only; never give intravenously.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}